Characterization of BRCA2 R3052Q variant in mice supports its functional impact as a low-risk variant
Open Access
- 18 November 2023
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (11) , 1-10
Abstract
Pathogenic variants in BRCA2 are known to significantly increase the lifetime risk of developing breast and ovarian cancers. Sequencing-based genetic testing has resulted in the identification of thousands of BRCA2 variants that are considered to be variants of uncertain significance (VUS) because the disease risk associated with them is unknown. One such variant is p.Arg3052Gln, which has conflicting interpretations of pathogenicity in the ClinVar variant database. Arginine at position 3052 in BRCA2 plays an important role in stabilizing its C-terminal DNA binding domain. We have generated a knock-in mouse model expressing this variant to examine its role on growth and survival in vivo. Homozygous as well as hemizygous mutant mice are viable, fertile and exhibit no overt phenotype. While we did not observe any hematopoietic defects in adults, we did observe a marked reduction in the in vitro proliferative ability of fetal liver cells that were also hypersensitive to PARP inhibitor, olaparib. In vitro studies performed on embryonic and adult fibroblasts derived from the mutant mice showed significant reduction in radiation induced RAD51 foci formation as well as increased genomic instability after mitomycin C treatment. We observed mis-localization of a fraction of R3052Q BRCA2 protein to the cytoplasm which may explain the observed in vitro phenotypes. Our findings suggest that BRCA2 R3052Q should be considered as a hypomorphic variant.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (NIH Intramural Program)
This publication has 43 references indexed in Scilit:
- A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair ActivityCancer Research, 2013
- Mutational Processes Molding the Genomes of 21 Breast CancersCell, 2012
- Plasticity of BRCA2 Function in Homologous Recombination: Genetic Interactions of the PALB2 and DNA Binding DomainsPLOS Genetics, 2011
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11Cell, 2011
- A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an exampleBMC Cancer, 2009
- A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2genes based on cancer family historyBreast Cancer Research, 2009
- Mouse embryonic stem cell–based functional assay to evaluate mutations in BRCA2Nature Medicine, 2008
- Functional Assays for Classification ofBRCA2Variants of Uncertain SignificanceCancer Research, 2008
- Biochemistry of Meiotic Recombination: Formation, Processing, and Resolution of Recombination Intermediates2008
- DSS1 is required for the stability of BRCA2Oncogene, 2005